Olmesartan Medoxomil
Olmesartan Medoxomil is a pharmaceutical drug with 39 clinical trials. Historical success rate of 97.2%.
Success Metrics
Based on 35 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
3
Mid Stage
32
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
97.2%
35 of 36 finished
2.8%
1 ended early
0
trials recruiting
39
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Observational Study to Evaluate the Therapeutic Effectiveness and Safety of Olomax Tab
A Randomized, Double Blind Study To Compare The Effects Of Olmesartan Medoxomil Versus Placebo In Patients With Established Atherosclerosis
s086 Tablets in the Treatment of Mild to Moderate Essential Hypertension
Efficacy and Safety of Valsartan and Amlodipine (± HCTZ) in Adults With Moderate, Inadequately Controlled Hypertension
Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension
Clinical Trials (39)
Observational Study to Evaluate the Therapeutic Effectiveness and Safety of Olomax Tab
A Randomized, Double Blind Study To Compare The Effects Of Olmesartan Medoxomil Versus Placebo In Patients With Established Atherosclerosis
s086 Tablets in the Treatment of Mild to Moderate Essential Hypertension
Efficacy and Safety of Valsartan and Amlodipine (± HCTZ) in Adults With Moderate, Inadequately Controlled Hypertension
Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension
The Confirmatory Olmesartan Plaque Regression Study
Amlodipine as add-on to Olmesartan in Hypertension
Study of Co-administration of Olmesartan Medoxomil Plus Amlodipine in Patients With Mild to Severe Hypertension
Study to Determine if Olmesartan Medoxomil Has the Potential to Benefit the Cardiovascular System in Terms of Arterial Protection
Olmesartan as an add-on to Amlodipine in Hypertension
Study of CS-3150 Compared to Olmesartan in Patients With Essential Hypertension
Angiotensin II Blockade and Inflammation in Obesity
Fimasartan Achieving SBP Target (FAST) Study
Efficacy and Safety of a Therapy Change From Candesartan 32 mg to Fixed Combination of Olmesartan 40 mg/Amlodipine 10 mg
An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Patients With Type II Diabetes
Assessment of Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescent Patients With High Blood Pressure
Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II Essential Hypertension
Supplemental Benefit of Angiotensin Receptor Blocker in Hypertensive Patients With Stable Heart Failure Using Olmesartan
Drug Interaction Study of Olmesartan in Healthy Chinese Volunteers
Treatment of High Blood Pressure Using Olmesartan With Hydrochlorothiazide Compared to an ACE Inhibitor With a Calcium Channel Blocker
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 39